secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2022-10-18T23:59:59+00:00
Accession:  0001213900-22-064735
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma hires Eric Weisblum as CEO with $350K salary, extends Columbia research pact
--------------------------------------------------------------------------------

- Eric Weisblum appointed CEO; base salary $350K/yr, signing bonus $100K, annual bonus up to $350K.
- Severance includes 24 months base salary, COBRA coverage, and prorated bonus on termination without cause or change in control.
- Columbia University agreement extended; option to license SPC-14 (Alzheimer's) and SPC-15 (stress-induced anxiety).
- CFO Daniel Ryweck salary increased to $60K/yr per amendment dated October 12, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390022064735/0001213900-22-064735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390022064735/ea167262-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-064735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer